Safety Evaluation of Ivabradine and Beta Blockers for Acute Heart Failure with Sinus Tachycardia

Safety Evaluation of Ivabradine and Beta Blockers for Acute Heart Failure with Sinus Tachycardia - Safety Evaluation of Ivabradine and Beta Blockers for Acute Heart Failure with Sinus Tachycardia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056935

Enrollment

100

Registered

2025-04-01

Start date

2025-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HFrEF patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: This retrospective study collected data on HFrEF patients with the first apparent heart failure treated as outpatients at three centers between 2019 and 2023. Heart failure was defined in this study according to criteria established in the guidelines of the Japanese Society of Cardiology. The enrollment criteria for the study stipulated that patients fulfilling the following conditions were eligible for inclusion: NT-pro BNP level of > 1000 pg/mL at the first outpatient visit New York Heart Association (NYHA) classification 2 or 3 degree Sinus tachycardia at the first outpatient visit Use of beta-blockers or ivabradine at the first visit LVEF < 40%

Exclusion criteria

Exclusion criteria: Exclusion criteria were ischemic heart disease, moderate or severe primary valve failure, and dialysis.

Design outcomes

Primary

Measure	Time frame
The primary endpoint was heart failure exacerbation events within one year, divided into beta-blocker and ivabradine treatment groups introduced at the first outpatient visit as a safety outcome.	—

Countries

Japan

Contacts

Public ContactTakahito Nasu

Iwate medical University Division of Cardiology, Department of Internal Medicine

tnasu@iwate-med.ac.jp019-613-7111

Outcome results